|D058186||Acute Kidney Injury NIH||0.21|
|D014947||Wounds and Injuries NIH||0.18|
|D016638||Critical Illness NIH||0.13|
There is one clinical trial.
ACEI-COVID-19 is a multicenter, randomized trial testing the hypothesis that stopping/replacing chronic treatment with ACE-inhibitors (ACEI) or angiotensin receptor blockers (ARB) improves outcomes in symptomatic SARS-CoV2-infected patients
Description: The minimal value of the SOFA Score will be 0 and the maximal value 24 points. All-cause death is classified as the maximum score (24 points). In case of a subclinical disease progress without need for hospitalization, the SOFA score will be 0.Measure: Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death Time: 30 days
Description: minimum score is 0, maximum score is 24; higher score indicates poor outcomeMeasure: Maximum and median maximum Sequential Organ Failure Assessment (SOFA) Score Time: 30 days
Description: high-flow, continuous positive airway pressure therapyMeasure: Rates of non-invasive ventilation Time: 30 days
Description: with causal relationship to stopping of ACEI/ARB therapyMeasure: Hospitalisation due to cardiac decompensation Time: 30 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports